At its meeting on 19 March our Board approved changes to the criteria we use to decide which treatments should be evaluated, to ensure more consistent, predictable and transparent decisions.
We've published a draft quality standard calling for yearly BMI and waist-to-height measurements to help prevent weight-related complications.
Leniolisib is the first ever treatment for activated phosphoinositide 3-kinase delta syndrome (APDS) licensed for use in the NHS in England.
Today we've recommended the first long-term daily pill to treat endometriosis that could transform how this painful condition is managed.
An end of year summary from our chief executive, Dr Sam Roberts.
A guide to the severity modifier and how it is leading to more positive recommendations overall from NICE.
Our chief medical officer, Professor Jonathan Benger, explains the crucial role the HST programme plays in encouraging innovation in the treatment of ultra-rare diseases. He also highlights why effective routing is essential to getting the best care to patients across the NHS.
Introducing the Medicines and Medical Devices Access Initiative (MMD): a new collaboration that aims to improve patient access to safe, clinically and cost-effective healthcare products.
